Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit tumor growth and angiogenesis. Covalent linkage of naproxen to human serum albumin (HSA) has been shown to target it efficiently to the liver and this may potentially be exploited for liver-selective inhibition of angiogenesis. With the aim of investigating the anti-angiogenic efficiency of NSAID-HSA conjugates in vitro, three NSAIDs, aspirin, ibuprofen, and naproxen were conjugated to HSA using different concentrations of their N-hydroxysuccinimide esters. Conjugation ratios from 10 to 50 were achieved and the conjugates retained a growth inhibitory effect on endothelial cells at or above the level of the non-conjugated NSAIDs in an in vitro angiogenesis assay.
Keywords: Angiogenesis, HUVEC, NSAID, HSA, conjugation
Protein & Peptide Letters
Title: Synthesis and Anti-Angiogenic Effect of Conjugates Between Serum Albumin and Non-Steroidal Anti-Inflammatory Drugs
Volume: 17 Issue: 1
Author(s): B. Kjær, C. Struve, T. Friis, A.-M. Engel, N. H. Beyer, P. Hojrup and G. Houen
Affiliation:
Keywords: Angiogenesis, HUVEC, NSAID, HSA, conjugation
Abstract: Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit tumor growth and angiogenesis. Covalent linkage of naproxen to human serum albumin (HSA) has been shown to target it efficiently to the liver and this may potentially be exploited for liver-selective inhibition of angiogenesis. With the aim of investigating the anti-angiogenic efficiency of NSAID-HSA conjugates in vitro, three NSAIDs, aspirin, ibuprofen, and naproxen were conjugated to HSA using different concentrations of their N-hydroxysuccinimide esters. Conjugation ratios from 10 to 50 were achieved and the conjugates retained a growth inhibitory effect on endothelial cells at or above the level of the non-conjugated NSAIDs in an in vitro angiogenesis assay.
Export Options
About this article
Cite this article as:
Kjær B., Struve C., Friis T., Engel A.-M., Beyer H. N., Hojrup P. and Houen G., Synthesis and Anti-Angiogenic Effect of Conjugates Between Serum Albumin and Non-Steroidal Anti-Inflammatory Drugs, Protein & Peptide Letters 2010; 17(1) . https://dx.doi.org/10.2174/092986610789909511
DOI https://dx.doi.org/10.2174/092986610789909511 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Current Guidelines and Strategies in Management of Renal Vein Thrombosis
Current Pediatric Reviews Ionic Liquids for Topical Delivery in Cancer
Current Medicinal Chemistry Carbonic Anhydrase IX as a Target for Designing Novel Anticancer Drugs
Current Medicinal Chemistry Natural Products Targeting EGFR Signaling Pathways as Potential Anticancer Drugs
Current Protein & Peptide Science Clinical Efficacy and Effectiveness of Ursodeoxycholic Acid in Cholestatic Liver Diseases
Current Clinical Pharmacology Mechanism-based Combinations with Pim Kinase Inhibitors in Cancer Treatments
Current Pharmaceutical Design Manganese Superoxide Dismutase (Sod2) and Redox-Control of Signaling Events That Drive Metastasis
Anti-Cancer Agents in Medicinal Chemistry Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities
Current Pharmaceutical Design Editorial [Hot Topic: Protein Kinase Inhibitors: Current Strategies and Future Prospects (Executive Guest Editor: Julio Caballero)]
Current Pharmaceutical Design Fibroblast Growth Factors/Fibroblast Growth Factor Receptors as Targets for the Development of Anti-Angiogenesis Strategies
Current Pharmaceutical Design Cytotoxic and Anticancer Activities of Isatin and Its Derivatives: A Comprehensive Review from 2000-2008
Anti-Cancer Agents in Medicinal Chemistry Protective and Therapeutic Effects of Ghrelin in the Gut
Current Medicinal Chemistry Synthesis, Biological Evaluation and Docking Studies of Sorafenib Derivatives N-(3-fluoro-4-(pyridin-4-yloxy)phenyl)-4(5)-phenylpicolinamides
Medicinal Chemistry Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Current Pharmaceutical Design Evaluation of Novel Biomarkers of Acute Kidney Injury: The Possibilities and Limitations
Current Medicinal Chemistry Targeting Regulatory T Cells for Anticancer Therapy
Mini-Reviews in Medicinal Chemistry Targeting the p53 Pathway of Apoptosis
Current Pharmaceutical Design RAN GTPase as a Target for Cancer Therapy: Ran Binding Proteins
Current Molecular Medicine Gut-liver Axis and Microbiota in NAFLD: Insight Pathophysiology for Novel Therapeutic Target
Current Pharmaceutical Design Proteomic Approaches for the Study of Transgelins as Tumor-associated Proteins and Potential Biomarkers
Current Proteomics